FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2033718586> ?p ?o ?g. }

• W2033718586 endingPage "5816" @default.
• W2033718586 startingPage "5806" @default.
• W2033718586 abstract "Article3 November 2003free access C/EBPβ: a major PML–RARA-responsive gene in retinoic acid-induced differentiation of APL cells Estelle Duprez Corresponding Author Estelle Duprez Present address: Centre d'Immunologie de Marseille, Luminy, case 906, 13288 Marseille, cedex 09, France Search for more papers by this author Katharina Wagner Katharina Wagner Harvard Institutes of Medicine, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA, 02115 USA Search for more papers by this author Heike Koch Heike Koch Harvard Institutes of Medicine, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA, 02115 USA Search for more papers by this author Daniel G. Tenen Daniel G. Tenen Harvard Institutes of Medicine, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA, 02115 USA Search for more papers by this author Estelle Duprez Corresponding Author Estelle Duprez Present address: Centre d'Immunologie de Marseille, Luminy, case 906, 13288 Marseille, cedex 09, France Search for more papers by this author Katharina Wagner Katharina Wagner Harvard Institutes of Medicine, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA, 02115 USA Search for more papers by this author Heike Koch Heike Koch Harvard Institutes of Medicine, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA, 02115 USA Search for more papers by this author Daniel G. Tenen Daniel G. Tenen Harvard Institutes of Medicine, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA, 02115 USA Search for more papers by this author Author Information Estelle Duprez 2, Katharina Wagner1, Heike Koch1 and Daniel G. Tenen1 1Harvard Institutes of Medicine, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA, 02115 USA 2Present address: Centre d'Immunologie de Marseille, Luminy, case 906, 13288 Marseille, cedex 09, France *Corresponding author. E-mail: [email protected] The EMBO Journal (2003)22:5806-5816https://doi.org/10.1093/emboj/cdg556 PDFDownload PDF of article text and main figures. ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinked InMendeleyWechatReddit Figures & Info In acute promyelocytic leukemia (APL), the translocation t(15;17) induces a block at the promyelocytic stage of differentiation in an all-trans-retinoic acid (ATRA)-responsive manner. Here we report that upon treatment with ATRA, t(15;17) cells (NB4) reveal a very rapid increase in protein level and binding activity of C/EBPβ, a C/EBP family member, which was not observed in an ATRA-resistant NB4 cell line. We further provide evidence that ATRA mediates a direct increase of C/EBPβ, only in PML–RARA (promyelocytic leukemia–retinoic acid receptor α)-expressing cells. In addition, transactivation experiments indicate that the PML–RARA fusion protein, but not PML–RARA mutants defective in transactivation, strongly transactivates the C/EBPβ promoter. These results suggest that PML–RARA mediates ATRA-induced C/EBPβ expression. Finally, we demonstrate the importance of C/EBPβ in granulocytic differentiation. We show that not only does C/EBPβ induce granulocytic differentiation of non-APL myeloid cell lines independent of addition of ATRA or other cytokines, but also that C/EBPβ induction is required during ATRA-induced differentiation of APL cells. Taken together, C/EBPβ is an ATRA-dependent PML–RARA target gene involved in ATRA-induced differentiation of APL cells. Introduction Acute myeloid leukemias are often associated with specific chromosomal translocations that rearrange genes important for the commitment and the differentiation of hematopoietic cells. The t(15;17) translocation found in acute promyelocytic leukemia (APL) juxtaposes the promyelocytic (PML) gene to the retinoic acid receptor α (RARA) gene (Borrow et al., 1990; de The et al., 1990). It is believed that the aberrant PML–RARA fusion protein resulting from the translocation plays a role in the accumulation of the blasts arrested at the promyelocytic stage. This hypothesis is supported by studies of the expression of PML–RARA in transgenic mice, resulting in the development of leukemia with striking APL features (Brown et al., 1997; Grisolano et al., 1997; He et al., 1997). The interesting feature of the PML–RARA-bearing blasts is that they are acutely sensitive to therapeutic doses of all-trans-retinoic acid (ATRA) which is used effectively for the treatment of t(15;17) patients (Castaigne et al., 1990; for a review see Mistry et al., 2003). However, the precise mechanism by which the PML–RARA fusion protein blocks the cells at the promyelocytic stage, and how retinoic acid (RA) reverses this block is still unclear. It is believed that PML–RARA acts as a dominant-negative factor on both the RARA and PML pathways (de The et al., 1991; Kakizuka et al., 1991). It has been shown that PML–RARA retains most functional domains of the RARA protein and behaves as an abnormal RA receptor with altered transactivation properties, suggesting a defect in the RA pathway to be responsible for the promyelocytic block. This has been strongly supported by experiments showing that PML–RARA recruits co-repressors and histone deacetylase that cannot be dissociated with physiological doses of RA, thus inhibiting RA-induced transcriptional activation (Grignani et al., 1998; He et al., 1998; Lin et al., 1998). However, recently it has become evident that disruption in the RA signaling pathway does not afford an explanation as to how the cells become specifically blocked at the promyelocytic stage since granulocyte lineage commitment is not impaired in RARA and retinoic acid receptor γ (RARG)-deficient mice (Kastner et al., 2001). The sensitivity of promyelocytes in APL to ATRA remains an enigma. One explanation is that PML–RARA not only participates in the block of cell differentiation, but is also involved in the response of cells to ATRA. PML–RARA has been shown to homodimerize and act as a potent transcriptional repressor, acquiring an oncogenic potential which is reversible upon ATRA treatment (Lin and Evans, 2000; Minucci et al., 2000). Moreover, PML–RARA has been involved in the regulation of genes during APL differentiation (Park et al., 1999; Moog-Lutz et al., 2001). In addition, ATRA resistance, a major problem in ATRA treatment, is mainly associated with defects in the RARA E-domain of PML–RARA (Imaizumi et al., 1998; Duprez et al., 2000). These findings highlight the role of the fusion protein in mediating the sensitivity of APL cells to ATRA. In this work, we tested the hypothesis that ATRA could target members of the leucine zipper transcription factor family, the CCAAT/enhancer-binding protein (C/EBP) family, during APL differentiation. These transcription factors are implicated in the growth or the differentiation of several tissues or cell lineages including the myeloid lineage (for a review see Lekstrom-Himes and Xanthopoulos, 1998). In myeloid development, the effect of the C/EBP family on cell proliferation and differentiation is mediated by their ability to bind DNA (often containing the sequence CCAAT) and control gene expression (reviewed in Tenen et al., 1997), although recent studies provide evidence that these factors also regulate cell fate by protein–protein interaction, independent of their transcriptional activity (reviewed in McKnight, 2001). Three members of this family, C/EBPα, C/EBPβ and C/EBPϵ have been shown to be involved at different stages of myeloid development. C/EBPα plays a critical role for the engagement of the cells to the granulocytic lineage (Zhang et al., 1997; Radomska et al., 1998), while C/EBPϵ is important late in the granulocytic differentiation process (Yamanaka et al., 1997). However, the role of C/EBPβ is less clear. Although C/EBPβ knockout mice do not show any defects in myeloid differentiation, recent reports show that C/EBPβ can drive immature cells into granulocytes (Popernack et al., 2001; Iwama et al., 2002). The apparent lack of any myeloid defects in C/EBPβ mice may suggest that overlapping expression of C/EBP members provides functional redundancy among the different members (Hu et al., 1998). Here, we report that ATRA targets C/EBPβ during APL differentiation. We show that ATRA increases C/EBPβ activity and we demonstrate that this activation is due to an increase in C/EBPβ RNA and protein levels and is one of the earliest events following ATRA treatment. We show that PML–RARA mediates ATRA-induced upregulation of C/EBPβ through the C/EBPβ proximal promoter and that ATRA resistance of APL cells correlates with the loss of C/EBPβ induction. ATRA-independent expression of C/EBPβ can drive multipotent hematopoietic cells to granulocytic differentiation. Inhibition of C/EBPβ, obtained after using a dominant-negative C/EBP or using small interfering RNA (siRNA) against C/EBPβ, reduces ATRA-induced maturation of APL cells. Therefore, we propose that C/EBPβ is a major target of PML–RARA during APL differentiation. Results An increase in C/EBP binding activity is an early event in APL cells in response to ATRA Because of the known role of C/EBP proteins in mediating granulocytic differentiation, we investigated C/EBP activity during ATRA-induced APL differentiation. Electrophoretic mobility shift assays (EMSAs) were performed using a C/EBP-binding site probe from the human granulocyte colony-stimulating factor (G-CSF) receptor promoter (Smith et al., 1996) with nuclear extract from APL ATRA-sensitive NB4 cells. Consistent with previous findings (Lutz et al., 2001), C/EBP binding was detected in NB4 cells (Figure 1A, lane 3). Addition of specific antibody against either C/EBPα, C/EBPβ or C/EBPϵ resulted for each family member tested in a partial supershift of the protein–oligonucleotide complex (Figure 1A, lanes 4–6), indicating that these three CEBP proteins were part of the DNA–protein complex initially observed. EMSA of nuclear extract from NB4 cells after ATRA stimulation revealed substantial modification in the DNA binding profile of C/EBP proteins. Levels of C/EBPα binding did not change within 24 h of ATRA treatment (Figure 1A, lane 8), and disappeared after 48 h (Figure 1A, lanes 12 and 16). In contrast, we observed an increase in C/EBPβ binding after 24 h of ATRA treatment (Figure 1A, lanes 9 and 13) as well as an increase of C/EBPϵ binding (Figure 1A, lanes 10, 14 and 18). The C/EBP DNA binding profile was not modified upon ATRA treatment of NB4-R2 cells, an NB4 subclone which is resistant to ATRA treatment (Duprez et al., 2000) (Figure 1B, lanes 3–18). These data demonstrate that the activity of different C/EBP proteins is modulated upon ATRA treatment and suggest that there is a correlation between ATRA-induced C/EBP binding modification and ATRA-induced APL differentiation. Figure 1.ATRA induces changes in the C/EBP DNA binding profile during promyelocytic differentiation. EMSA analysis of nuclear extracts from NB4 (A) and NB4-R2 cells (B) treated with ATRA. A double-stranded oligonucleotide including the C/EBP-binding site from the G-CSF receptor was radiolabeled with 32P and incubated in the absence (free probe; lane 1) or presence of 10 μg of nuclear extracts from cells which were untreated (lanes 3–6), or treated for 24 (lanes 7–10), 48 (lanes 11–14) and 72 h (lanes 15–18) with ATRA. For competition analysis, a 50-fold molar excess of unlabeled oligonucleotide was used (lane 2). Antisera against C/EBPα (α), C/EBPβ (β) or C/EBPϵ (ϵ) were added to the binding reaction. Supershifted complexes are indicated with an arrow. Free probe was present in excess in each lane (shown for A only, but similar results apply to the EMSA shown in B and Figure 2). Download figure Download PowerPoint C/EBPϵ has been described as a target gene responsible for ATRA-induced differentiation (Park et al., 1999). We found an increase in the binding activity of both C/EBPβ and C/EBPϵ upon ATRA-mediated differentiation. Thus, we next sought to determine the temporal sequence of the two events by studying the binding activity of C/EBPs following a short exposure of NB4 cells to ATRA. We found that C/EBPα binding activity was not modified during 8 h of ATRA treatment, whereas C/EBPβ activity was stimulated as early as 2 h following ATRA treatment (supershifted bands, Figure 2A) and C/EBPϵ required at least 8 h to display an increase in binding activity (Figure 2A). Thus, C/EBPβ binding activity preceded that of C/EBPϵ. Bone marrow cells from an APL patient were subjected to EMSA, and we demonstrated that in vitro treatment with ATRA for 15 h increased C/EBPβ binding in the APL sample, resembling that seen in the NB4 cell line (Figure 2B). Our results thus implicate C/EBPβ as a new RA target in ATRA-induced APL differentiation. Figure 2.C/EBPβ DNA binding activity is rapidly enhanced during ATRA-mediated differentiation of APL cells. (A) NB4 cells were treated with 1 μM ATRA for 2 (lanes 4–6), 4 (lanes 7–9) and 8 h (lanes 10–12). EMSAs were performed using the same conditions as in Figure 1. DNA–C/EBP complexes were characterized by supershift experiments using antisera against C/EBPα (α), C/EBPβ (β) or C/EBPϵ (ϵ). (B) C/EBPα and C/EBPβ binding profile in primary APL cells. Untreated cells and cells treated for 15 h with 1 μM ATRA were subjected to EMSA analysis using the same conditions as in (A). Download figure Download PowerPoint ATRA regulates C/EBPβ expression through PML–RARA Post-transcriptional modification of C/EBPβ can enhance C/EBPβ transcriptional activity by enhanced DNA binding (Poli et al., 1990). Thus, we were interested in investigating the mechanism by which ATRA enhances C/EBPβ binding. We used a C/EBPβ-specific antibody to analyze the relative protein level in nuclear extracts from cells treated for varying lengths of time with ATRA. In untreated NB4 cells, we were unable to detect the C/EBPβ protein by immunoblotting (Figure 3, upper panel), although the more sensitive EMSA revealed the presence of the protein (Figure 1). Nonetheless, expression of C/EBPβ protein was markedly increased following ATRA treatment. The augmentation in relative abundance of C/EBPβ protein following ATRA treatment (Figure 3, upper panel) correlated with the kinetics observed for the increase in DNA binding activity (Figure 1). Moreover, no change in C/EBPβ protein level was observed in the resistant cell line NB4-R2 (Figure 3, upper panel). However, analyses of the same extracts using a C/EBPϵ-specific antibody failed to detect any significant changes in expression level of C/EBPϵ isoforms (32 and 27 kDa) after a short exposure of the cells to ATRA. In agreement with previously published data (Chih et al., 1997), the smaller, 27 kDa isoform increased in abundance after longer exposure of ATRA (Figure 3, lower panel). Therefore, we conclude that ATRA activates C/EBPβ activity by increasing the nuclear level of the protein and that this effect precedes C/EBPϵ upregulation. Figure 3.The increase in C/EBPβ protein after ATRA treatment reflects the increase in DNA binding activity. Nuclear extracts from ATRA-sensitive (NB4) and ATRA-resistant (NB4-R2) cells were tested for C/EBPβ and C/EBPϵ expression by western blotting following ATRA treatment. The membranes were incubated with antiserum against C/EBPβ (upper panel) and then stripped and incubated with an antiserum against C/EBPϵ (lower panel). The arrows designate the bands corresponding to the 43 kDa C/EBPβ isoform, as well as the 32 and 27 kDa C/EBPϵ isoforms. On the left of the figure, specificity of the C/EBPβ antibody is shown using extracts from untransfected CV1cells and from CV1 cells transfected with a human C/EBPβ cDNA. Download figure Download PowerPoint To analyze further the mechanisms involved in ATRA-induced C/EBPβ upregulation, we studied the expression of C/EBPβ RNA. In agreement with the increase in protein levels, C/EBPβ RNA expression was increased following exposure of the NB4 cells to ATRA, while no induction was observed in the NB4-R2 resistant cells (Figure 4A). In addition, we also observed the same pattern of ATRA-induced C/EBPβ induction in another RA-sensitive APL cell line, HT93 (Figure 4A), indicating that this effect is not an artifact of the NB4 cell system. To study the APL-specific nature of C/EBPβ induction by ATRA, we took advantage of the U937-derived cell lines, U937-PR9 and U937-B412 which contain respectively a zinc-inducible PML–RARA and PLZF–RARA (Ruthardt et al., 1997). Using this system, we demonstrated that the level of C/EBPβ mRNA expression was strongly enhanced with ATRA in PML–RARA-expressing cells (Figure 4B). This enhanced expression required the presence of the PML–RARA fusion protein, since C/EBPβ remained only a little responsive to ATRA in U937-PR9 cells that were not pre-treated with zinc. More interestingly, induction of the fusion protein PLZF–RARA that is associated with an ATRA-resistant form of APL has no effect on C/EBPβ expression after ATRA treatment (Figure 4B). Treatment of NB4 cells for short periods of time revealed that the increase in C/EBPβ RNA occurred after only 1 h. The expression profile of C/EBPβ RNA following ATRA treatment was not perturbed by pre-treating the cells with cycloheximide, indicating that de novo protein synthesis is not required for ATRA to exert its effect (Figure 4C, left panel). The same short ATRA treatment did not modify C/EBPβ RNA in myeloid U937-PR9 cells in which PML–RARA was not expressed (Figure 4C, middle panel) but strongly enhanced C/EBPβ RNA in the same cells pre-treated with zinc, similar to that observed in NB4 cells (Figure 4C, right panel). These observations indicate that the direct induction of C/EBPβ mRNA by ATRA is PML–RARA specific. Given the literature showing that prolonged ATRA treatment results in PML–RARA degradation, the presence of PML–RARA was checked in the nuclear extract of NB4 cells after a short time of ATRA stimulation (Figure 4D). For the 4 h treatment time tested, we observe no degradation of the PML–RARA fusion protein. Taken together, our data demonstrate that ATRA directly regulates C/EBPβ expression and that this regulation requires the presence of the PML–RARA fusion protein. Figure 4.The presence of PML–RARA is required to rapidly induce C/EBPβ RNA. (A) Northern blot analysis of total RNA isolated from NB4, NB4-R2 and HT93 cells untreated or treated with 1 μM ATRA for the indicated time. The 28S rRNA level is shown as a loading control. (B) Comparison by northern blot of C/EBPβ induction after ATRA treatment between PML–RARA- and PLZF–RARA-expressing cells. PML–RARA and PLZF–RARA were induced respectively by pre-treating the U937-PR9 cells or the U937-B412 cells with zinc for 15 h. (C) Northern blot analysis of total RNA from NB4, U937-PR9 or zinc-pre-treated U937-PR9 cells untreated or treated with 1 μM ATRA for 1, 2 or 4 h in the absence (−) or presence (+) of cycloheximide (CHX). The 28S rRNA level is shown as a loading control. (D) Level of PML–RARA protein after a short period of ATRA treatment is revealed by western blot analysis of NB4 nuclear extracts using an anti-RARA antibody. (E) Northern blot analysis of the half-life of C/EBPβ mRNA in uninduced and ATRA-induced NB4 cells. NB4 cells were pre-treated with 1 μM ATRA for 4 h and then actinomycin D (10 μg/ml) was added for the indicated times to the cells prior to extraction of RNA. Results are presented as RNA level normalized against actin with respect to time. Download figure Download PowerPoint In order to investigate whether ATRA induced post-transcriptional stabilization of C/EBPβ mRNA, the mRNA half-life was measured in uninduced and ATRA-induced NB4 cells by exposing the cells to actinomycin D for the times indicated in Figure 4E. The average half-life of the mRNA was 2 h in both uninduced and ATRA-induced NB4 cells (Figure 4E), suggesting a transcriptional effect of ATRA rather than post-transcriptional mRNA stabilization accounting for the upregulation of steady-state level of C/EBPβ mRNA. ATRA treatment activates the C/EBPβ promoter in a PML–RARA-dependent manner ATRA is known to exert its effects by transcriptional activation via the heterodimer RAR/RXR (Perez et al., 1993), and transcriptional activation by ATRA has been shown to be mediated through an RA response element (RARE) motif composed of direct repeats of (A/G)G(G/T)TCA (Naar et al., 1991; Umesono et al., 1991). As our results suggested that ATRA was mediating PML–RARA activation of C/EBPβ transcription, we assessed the efficiency of PML–RARA in activating the C/EBPβ promoter in the absence or presence of ATRA. We subcloned 0.8 kb of the human C/EBPβ promoter region (bp −600 to +200) which includes the putative TATA-binding protein-binding site and transcriptional initiation site, into a luciferase (LUC) reporter vector (Figure 5A). Transfection of the resulting BetaP0.8LUC reporter construct into U937-PR9 cells demonstrated that the C/EBPβ promoter did not respond like a RA-responsive promoter. Treatment of the non-zinc-stimulated cells with ATRA failed to significantly transactivate the promoter, compared with the control RARE-LUC reporter plasmid (Figure 5B, compare lane 1 with lane 11). In contrast, the relative luciferase activity was enhanced in the presence of PML–RARA after ATRA treatment (Figure 5B, lane 2), showing that the C/EBPβ promoter region was activated only in the presence of the fusion protein after ATRA treatment (Figure 5B). This correlated well with our northern blot results (Figure 4), which demonstrated elevation of C/EBPβ expression exclusively in PML–RARA-expressing cells. Deletion analyses of the C/EBPβ promoter implicated the region between bp −112 and +56 as being important for this activation (Figure 5B). Figure 5.C/EBPβ promoter is specifically activated by PML–RARA in the presence of ATRA. (A) Schematic representation of promoter constructs used in transient transfections shown in (B) and (C). The white rectangle labeled ‘TATAA’ represents the putative TATA box of the C/EBPβ promoter. (B) U937-PR9 cells were transiently transfected with the different deletions of the C/EBPβ reporter constructs. PML–RARA induction was obtained by pre-treating U937-PR9 cells with zinc for 15 h. Relative luciferase activity in the absence (white bar) or presence (black bar) of 2 μM ATRA is presented. U937 cells (without PML–RARA) were treated with zinc for 15 h to control for the effect of zinc treatment. The RAREx3LUC reporter vector was used as a control for ATRA treatment. (C) C-terminal PML–RARA deletion mutants were tested for their ability to activate the C/EBPβ promoter in U937-PR9 cells. The BetaP0.3LUC reporter was co-transfected in non-zinc-stimulated U937-PR9 cells with expression vector for PML–RARA wild-type and mutants (lanes 3–5). Relative luciferase activity in the absence (white bar) or presence (black bar) of 2 μM ATRA is presented. Download figure Download PowerPoint To investigate whether the integrity of the fusion protein is necessary for the transactivation, C-terminal deletion mutants of PML–RARA were tested (Figure 5C). PML–RARAΔ903, a mutant which lacks half of α-helix 12 of the ligand-binding domain, could repress basal transcriptional activity but, importantly, this repression could not be overcome with ATRA treatment (Figure 5C, lane 4). Deletion of the F domain did not affect the transcription activity of PML–RARA (Figure 5C). These results demonstrate that a functional ligand-binding domain is required for the transactivation by PML–RARA. It is noteworthy that this Δ903 mutant has been shown to be expressed in the ATRA-resistant NB4 subclone NB4-R2 (Duprez et al., 2000). C/EBPβ can induce granulocytic differentiation of a multipotential hematopoietic cell line Our data strongly implicate an important role for C/EBPβ in ATRA-induced promyelocytic differentiation of APL cells and suggested that C/EBPβ directed differentiation. To determine whether C/EBPβ can induce hematopoietic cells to undergo differentiation to granulocytes, we used the multipotent K562 cell line as a model (Sutherland et al., 1986) that does not express C/EBPα, C/EBPβ or C/EBPϵ. Therefore, K562 cells were transduced with a pBabePuro retrovirus encoding either an estrogen receptor hormone-binding domain fused to C/EBPβ (C/EBPβ-ER) or the estrogen receptor hormone-binding domain alone (ER). When infected with the C/EBPβ-ER or ER viruses, the expressed exogenous proteins were located in the cytoplasm, thus partitioning any nuclear activities they might have (Figure 6A). However, upon treatment of infected cells with β-estradiol for 48 h, the exogenous protein translocated to the nucleus (Figure 6A, i), thus allowing the direct study of any associated nuclear C/EBPβ activity. Following β-estradiol treatment, the C/EBPβ-ER-infected cells developed morphological changes characteristic of granulocytic differentiation (Figure 6A, ii), the cells stained positive for the nitroblue tetrazolium (NBT) reduction assay (Figure 6A, iii) and showed an increase in CD11b expression (Figure 6B). In order to characterize further granulocytic differentiation following the induction of C/EBPβ, the expression of granulocytic-specific genes was analyzed by northern blot RNA prepared before and after varying times of β-estradiol treatment. C/EBPβ nuclear translocation led to the specific induction of G-CSF receptor and C/EBPϵ RNA (Figure 6C). Thus, in conclusion, the translocation of C/EBPβ into the nucleus of K562 cells drives the cells to differentiate into mature granulocytes as assessed by morphological changes, NBT reduction assay, expression of a cell surface differentiation marker and granulocyte-specific gene expression. Figure 6.C/EBPβ directs differentiation of a multipotent hematopoietic cell line. (A) β-Estradiol induces nuclear localization of the C/EBPβ-ER fusion protein followed by granulocytic differentiation. (i) Stably transfected K562 cells were subjected to immunofluorescence using an anti-C/EBPβ antibody after treatment for 24 h with vehicle only (left panel) or β-estradiol (right panel). Cell maturation was evaluated by morphology (ii) and by NBT reduction assay (iii) following 48 h of treatment with vehicle only (left panel) or β-estradiol (right panel). (B) Cell surface expression of CD11b was determined by FACS. Cells transfected with empty ER vector or with C/EBPβ-ER were treated with vehicle only or with β-estradiol for 72 h. (C) RNA expression of the G-CSF receptor (upper panel) or C/EBPϵ (lower panel) was assessed using northern blot analysis. As indicated in the figure, cells infected with empty vector (ER) or C/EBPβ-ER were treated for different times with β-estradiol. Download figure Download PowerPoint C/EBPβ activity is required for ATRA induction of APL cell differentiation To investigate further the role of C/EBPβ in APL cell differentiation, the effect of overexpression of a dominant-negative form of C/EBP was examined in U937-PR9 and NB4 cells. The dominant-negative C/EBP (A-C/EBP) contains an acid amphipathic helix juxtaposed to a 49 amino acid leucine zipper domain of C/EBP. This combination allows formation of stable heterodimer with other C/EBP proteins and inhibits C/EBP gene activation (Olive et al., 1996). By using a retrovirus-mediated gene transfer system (Iwama et al., 2002), we expressed A-C/EBP in PML–RARA-expressing cells. Following infection, cells were treated with ATRA and expression of the cell surface differentiation marker CD11b was evaluated (Figure 7). Cells transfected with the control empty vector or the green fluorescent protein (GFP)-negative population of A-C/EBP-infected cells exhibited an increase in expression of the CD11b marker upon ATRA treatment. The GFP-positive population from the A-C/EBP-infected cells did not show an increase of CD11b expression after ATRA treatment in either zinc-pre-treated U937-PR9 or NB4 cells (Figure 7). These data suggest that disruption of C/EBP function leads to a block in ATRA-induced APL cell differentiation. To look specifically for the involvement of C/EBPβ in the ATRA-regulated maturation process, we used DNA vector-based RNAi technology to suppress C/EBPβ expression in NB4 cells. NB4 cells were transfected with the empty vector MSCV-U6 or the MCV-U6-beta vector, and transfected cells were selected in media containing puromycin. One month after selection, cells were treated with ATRA. As shown as Figure 8A, cells that had been transfected with MSCV-U6-beta had a significantly reduced level of C/EBPβ expression in response to ATRA. The maturation state of the cells was assessed by morphology and we demonstrated a correlation between the low level of C/EBPβ expression (Figure 8A) and an immature shape of the cells (Figure 8B) in response to ATRA. Quantification of maturation was obtained by NBT reduction assay, and a poor response of the low C/EBPβ-expressing cells to ATRA treatment could be confirmed (Figure 8C). Figure 7.Inhibition of ATRA-induced granulocytic differentiation by a dominant-negative C/EBP. U937-PR9 (left panel) and NB4 (right panel) cells were infected with a virus expressing the dominant- negative form of C/EBP, A-C/EBP (bottom two panels) or mock virus (top panels). The infected cells were treated with ATRA to induce differentiation. CD11b expression in the GFP-negative cell population (bottom panels) or GFP-positive cell population (top two panels) was examined by flow cytometry 72 h after induction of differentiation. Download figure Download PowerPoint Figure 8.Reduction of C/EBPβ expression induces reduction of ATRA-induced differentiation of NB4 cells. (A) C/EBPβ expression was evaluated by northern blot after 4" @default.
• W2033718586 created "2016-06-24" @default.
• W2033718586 creator A5017993134 @default.
• W2033718586 date "2003-11-03" @default.
• W2033718586 modified "2023-10-03" @default.
• W2033718586 title "C/EBP : a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells" @default.
• W2033718586 cites W1486948598 @default.
• W2033718586 cites W1502074492 @default.
• W2033718586 cites W1502827779 @default.
• W2033718586 cites W1526134400 @default.
• W2033718586 cites W1550565578 @default.
• W2033718586 cites W1553544241 @default.
• W2033718586 cites W1579062391 @default.
• W2033718586 cites W1596579583 @default.
• W2033718586 cites W172730770 @default.
• W2033718586 cites W1750460473 @default.
• W2033718586 cites W1909732837 @default.
• W2033718586 cites W1930158841 @default.
• W2033718586 cites W1965388358 @default.
• W2033718586 cites W1970999814 @default.
• W2033718586 cites W1973079711 @default.
• W2033718586 cites W1974839297 @default.
• W2033718586 cites W1979895333 @default.
• W2033718586 cites W1981044274 @default.
• W2033718586 cites W1982342754 @default.
• W2033718586 cites W1983683479 @default.
• W2033718586 cites W1983925806 @default.
• W2033718586 cites W1987598864 @default.
• W2033718586 cites W2011467252 @default.
• W2033718586 cites W2012661561 @default.
• W2033718586 cites W2013481353 @default.
• W2033718586 cites W2022139382 @default.
• W2033718586 cites W2025471241 @default.
• W2033718586 cites W2037305906 @default.
• W2033718586 cites W2042117566 @default.
• W2033718586 cites W2050259910 @default.
• W2033718586 cites W2054737276 @default.
• W2033718586 cites W206145882 @default.
• W2033718586 cites W2063083122 @default.
• W2033718586 cites W2066756232 @default.
• W2033718586 cites W2075232957 @default.
• W2033718586 cites W2079526924 @default.
• W2033718586 cites W2101615813 @default.
• W2033718586 cites W2110934492 @default.
• W2033718586 cites W2119778730 @default.
• W2033718586 cites W2125564519 @default.
• W2033718586 cites W2127621383 @default.
• W2033718586 cites W2134429215 @default.
• W2033718586 cites W2140439419 @default.
• W2033718586 cites W2144284827 @default.
• W2033718586 cites W2149902033 @default.
• W2033718586 cites W2152729220 @default.
• W2033718586 cites W2156718542 @default.
• W2033718586 cites W2166788322 @default.
• W2033718586 cites W2418727512 @default.
• W2033718586 cites W2464733971 @default.
• W2033718586 cites W2465507161 @default.
• W2033718586 cites W321874077 @default.
• W2033718586 doi "https://doi.org/10.1093/emboj/cdg556" @default.
• W2033718586 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/275413" @default.
• W2033718586 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14592978" @default.
• W2033718586 hasPublicationYear "2003" @default.
• W2033718586 type Work @default.
• W2033718586 sameAs 2033718586 @default.
• W2033718586 citedByCount "151" @default.
• W2033718586 countsByYear W20337185862012 @default.
• W2033718586 countsByYear W20337185862013 @default.
• W2033718586 countsByYear W20337185862014 @default.
• W2033718586 countsByYear W20337185862015 @default.
• W2033718586 countsByYear W20337185862016 @default.
• W2033718586 countsByYear W20337185862017 @default.
• W2033718586 countsByYear W20337185862018 @default.
• W2033718586 countsByYear W20337185862019 @default.
• W2033718586 countsByYear W20337185862020 @default.
• W2033718586 countsByYear W20337185862021 @default.
• W2033718586 countsByYear W20337185862022 @default.
• W2033718586 countsByYear W20337185862023 @default.
• W2033718586 crossrefType "journal-article" @default.
• W2033718586 hasAuthorship W2033718586A5017993134 @default.
• W2033718586 hasBestOaLocation W20337185861 @default.
• W2033718586 hasConcept C104317684 @default.
• W2033718586 hasConcept C148738053 @default.
• W2033718586 hasConcept C153911025 @default.
• W2033718586 hasConcept C2781121885 @default.
• W2033718586 hasConcept C54355233 @default.
• W2033718586 hasConcept C86803240 @default.
• W2033718586 hasConcept C95444343 @default.
• W2033718586 hasConceptScore W2033718586C104317684 @default.
• W2033718586 hasConceptScore W2033718586C148738053 @default.
• W2033718586 hasConceptScore W2033718586C153911025 @default.
• W2033718586 hasConceptScore W2033718586C2781121885 @default.
• W2033718586 hasConceptScore W2033718586C54355233 @default.
• W2033718586 hasConceptScore W2033718586C86803240 @default.
• W2033718586 hasConceptScore W2033718586C95444343 @default.
• W2033718586 hasIssue "21" @default.
• W2033718586 hasLocation W20337185861 @default.
• W2033718586 hasLocation W20337185862 @default.
• W2033718586 hasLocation W20337185863 @default.

• next